HZ characteristics of participants
| HZ and vaccine characteristics . | Data . |
|---|---|
| VZV Immunoglobulin G | |
| Positive | 146 (92) |
| Negative | 9 (6) |
| Indeterminate | 3 (2) |
| HZ prior to transplant | |
| Yes | 22 (14) |
| No | 135 (85) |
| Unknown | 1 (1) |
| ZVL prior to transplant | |
| Yes | 29 (18) |
| No | 113 (72) |
| Unknown | 16 (10) |
| Time from transplantation to V1, median (IQR), d | 280.50 (267.0-407.0) |
| Time between V1 and V2, median (IQR), d | 91.0 (70.0-105.0) |
| Active chronic GVHD | |
| At V1 | 60 (38) |
| At V2* | 61 (41) |
| Systemic immunosuppression | |
| At V1 | 112 (71) |
| At V2 | 90 (60) |
| Coadministered vaccines | |
| At V1 | 148 (94) |
| At V2 | 126 (84) |
| Antiviral prophylaxis† | |
| At V1 | 157 (99) |
| At V2 | 147 (98) |
| HZ and vaccine characteristics . | Data . |
|---|---|
| VZV Immunoglobulin G | |
| Positive | 146 (92) |
| Negative | 9 (6) |
| Indeterminate | 3 (2) |
| HZ prior to transplant | |
| Yes | 22 (14) |
| No | 135 (85) |
| Unknown | 1 (1) |
| ZVL prior to transplant | |
| Yes | 29 (18) |
| No | 113 (72) |
| Unknown | 16 (10) |
| Time from transplantation to V1, median (IQR), d | 280.50 (267.0-407.0) |
| Time between V1 and V2, median (IQR), d | 91.0 (70.0-105.0) |
| Active chronic GVHD | |
| At V1 | 60 (38) |
| At V2* | 61 (41) |
| Systemic immunosuppression | |
| At V1 | 112 (71) |
| At V2 | 90 (60) |
| Coadministered vaccines | |
| At V1 | 148 (94) |
| At V2 | 126 (84) |
| Antiviral prophylaxis† | |
| At V1 | 157 (99) |
| At V2 | 147 (98) |